In this prospective cohort study, CD19-directed chimeric antigen receptor (CAR) T-cell therapy was found to elicit a complete response in eleven patients with autoimmune hemolytic anemia who had ...
Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, ...
Not all patients respond well to chimeric antigen receptor (CAR) T cell therapies, which reprogram a patient’s own immune cells to recognize and attack cancer. A way to optimize these treatments is to ...
Marker Therapeutics, Inc. has announced a collaboration with Cellipont Bioservices to support the cGMP manufacturing of MT-601, its lead Multi-Antigen Recognizing (MAR)-T cell therapy, currently in ...
To view the event online, investors can register and access the webcast through Marker’s Investor Relations website under “Events and Presentations”.
HOUSTON, June 17, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the ...
News-Medical.Net on MSN
Alzheimer’s plaques decline after CAR-T immune cell treatment in preclinical study
By Hugo Francisco de Souza A novel CAR-T cell approach targets amyloid plaques in preclinical Alzheimer models, raising the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results